Aptevo Therapeutics Inc. (NASDAQ:APVO) shares were unchanged first thing Thursday. The Seattle-based company, a clinical-stage biotechnology concern focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today reported financial results for the quarter ended September 30, 2025.
APVO raised $18.7 million in the third quarter, $4.1 million since quarter end, extends cash runway into 4Q26.
This morning’s news release goes on to say Aptevo had cash and cash equivalents, totaling $21.1 million.
During the third quarter of 2025, the Company raised $18.7 million, net under the Company's Standy Equity Purchase Agreement (SEPA) with Yorkville and the Company's ATM agreement with Roth. An additional $4.1 million, net was raised under the ATM agreement in October, bringing the proforma cash and cash equivalents at September 30, 2025, to $25.2 million.
Research and development expenses increased by $0.9 million, from $3.1 million for the three months ended September 30, 2024, to $4.0 million for the three months ended September 30, 2025.
Aptevo had a net loss of $7.5 million or $2.23 per share for the three months ended September 30, 2025, compared to a net loss of $5.1 million or $357.86 per share for the corresponding period in 2024.
APVO dipped one cent to $1.42.
Related Stories
